A double-blind, randomized study of denosumab versus zoledronic acid for the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma

被引：40

作者：

Henry, D. ^{[3
]}

von Moos, R. ^{[4
]}

Vadhan-Raj, S. ^{[5
]}

Hungria, V. ^{[6
]}

Spencer, A. ^{[7
]}

Hirsh, V. ^{[8
]}

Wang, J. ^{[2
]}

Jun, S. ^{[1
]}

Yeh, H. ^{[1
]}

Dansey, R. ^{[1
]}

机构：

[1] Amgen Inc, Hematol Oncol, Thousand Oaks, CA 91320 USA

[2] Amgen Inc, Biostat & Epidemiol, Thousand Oaks, CA 91320 USA

[3] Penn Oncol Hematol Associates Inc, Hematol, Philadelphia, PA USA

[4] Kantonsspital Graubunden, Chur, Switzerland

[5] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[6] Irmandade Santa Casa Misericordia Sao Paulo, Hematol, Sao Paulo, Brazil

[7] Alfred Hosp, Prahran, Vic 3181, Australia

[8] McGill Univ, Ctr Hlth, Montreal, PQ, Canada

来源：

EJC SUPPLEMENTS | 2009年 / 7卷 / 03期

关键词：

D O I：

10.1016/S1359-6349(09)72055-5

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：12 / 12

页数：1